Eli Lilly Aktie
| 1 013,81USD | -9,65USD | -0,94% |
WKN: 858560 / ISIN: US5324571083
Personal
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Personal am Ende des Jahres | 35 000 | 39 000 | 43 000 | 47 000 | 50 000 |
| Umsatz pro Mitarbeiter in Mio. EUR | 0,81 | 0,73 | 0,79 | 0,96 | 1,30 |
Bilanz (in Mio. USD) - Aktiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Umlaufvermögen | 18 452 | 18 035 | 25 727 | 32 740 | 55 629 |
| Summe Anlagevermögen | 30 354 | 31 455 | 38 279 | 45 975 | 56 847 |
| Summe Aktiva | 48 806 | 49 490 | 64 006 | 78 715 | 112 476 |
Bilanz (in Mio. USD) - Passiva
| 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|
| Summe Fremdkapital | 39 651 | 38 714 | 53 143 | 64 443 | 85 941 |
| Summe Eigenkapital | 9 155 | 10 775 | 10 864 | 14 272 | 26 535 |
| Summe Passiva | 48 806 | 49 490 | 64 006 | 78 715 | 112 476 |
Adresse
| Lilly Corporate Center, 46285 Indianapolis | |
| Telefon | +1 (317) 276-2000 |
| Internet | http://www.lilly.com |
Management
|
Anat Hakim
Secretary, Executive VP & General Counsel |
|
Andy Vicari
Senior Director & US Brand Leader-Insulins |
|
Carole Ho
Executive VP & President-Lilly Neuroscience |
|
Carolyn R. Bertozzi
Director |
|
Daniel M. Skovronsky
Chief Scientific Officer & Executive VP |
|
David A. Ricks
Chairman, President & Chief Executive Officer |
|
David Hyman
Chief Medical Officer |
|
Diogo Rau
Executive VP, Chief Information & Digital Officer |
|
Donald A. Zakrowski
Chief Accounting Officer & Vice President-Finance |
|
Edgardo Hernandez
President-Manufacturing Operations & Senior VP |
|
Eric Dozier
Chief People Officer & Executive Vice President |
|
Gabrielle G. Greene-Sulzberger
Independent Director |
|
Ilya Yuffa
Executive VP- Global Customer Capabilities |
|
Jacob S. van Naarden
President-Lilly Oncology & Executive VP |
|
Jamere Jackson
Independent Director |
|
Jennifer Oleksiw
Global Chief Customer Officer & Vice President |
|
Joe Fletcher
Investor Relations Contact |
|
Jon Erik Fyrwald
Independent Director |
|
Jon R. Moeller
Independent Director |
|
Juan Ricardo Luciano
Lead Independent Director |
|
Katherine Baicker
Independent Director |
|
Kim Macko
Head-Global Brand Development |
|
Kimberly H. Johnson
Independent Director |
|
Laura A. Lane
Vice President |
|
Lucas E. Montarce
Chief Financial Officer & Executive Vice President |
|
Mark Genovese
Senior Vice President-Immunology Development |
|
Mary Lynne Hedley
Independent Director |
|
Melissa Seymour
Executive Vice President-Global Quality |
|
Nathaniel R. Miles
Vice President-Strategic Initiatives |
|
Patrik Jonsson
Executive VP & President-Lilly International |
|
Ralph Alvarez
Independent Director |
|
Robert Conley
Development Leader-Neuroscience |
|
Robert J. Heine
Vice President-Medical Affairs |
|
Ruth Gimeno
Vice President |
|
Thomas Fuchs
Chief Artificial Intelligence Officer & Senior VP |
|
William G. Kaelin
Independent Director |
ETF-Sparplan
Oskar ist der einfache und intelligente ETF-Sparplan. Er übernimmt die ETF-Auswahl, ist steuersmart, transparent und kostengünstig.